| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:2085-2089.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Beneficial Impact of Preconditioning During PTCA on Creatine Kinase Release
From the Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Md.
Correspondence to Dr Warren K. Laskey, Cardiac Catheterization Laboratory, University of Maryland Medical Systems, 22 S Greene St, Room S3B08, Baltimore, MD 21201-1595. E-mail wlaskey{at}medicine.ab.umd.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Previous studies in humans have indicated that there is less ischemic dysfunction during PTCA when ischemic preconditioning is elicited. However, the clinical relevance of these observations remains unclear. The present study design tests the hypothesis that PTCA performed to elicit the preconditioning response would result in less myocardial necrosis as assessed by postprocedure creatine kinase (CK) levels
Methods and Results—Patients (n=150) undergoing PTCA for unstable ischemic syndromes were randomly assigned to receive a previously validated approach to PTCA-mediated preconditioning (PC) or an unrestricted approach to balloon angioplasty (UC). CK levels were determined at 8, 12, and, if necessary, 24 hours. Clinical success rates were equivalent for the 2 groups. However, the frequency of any CK elevation was significantly higher in the UC group (25%) than in the PC group (7.1%) (P<0.005). Multivariable analysis confirmed a significant effect of preconditioning on CK release.
Conclusions—A standardized protocol to elicit preconditioning during PTCA results in a significant reduction in the rate of CK elevation in a high-risk population. These observations support the clinical relevance of ischemic preconditioning in humans.
Key Words: ischemia • angioplasty • creatine kinase • balloon
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Agrowing number of experimental and clinical studies have identified the ability of myocardial tissue to protect itself from lethal ischemia. The name given to this phenomenon, ischemic preconditioning, was originally taken from studies in which the extent of myocardial necrosis after coronary artery occlusion was limited when preceded by a brief period of ischemia and subsequent reperfusion.1 Since these seminal studies, inquiries into the mechanism(s) and mediator(s) of preconditioning have proliferated.2 Moreover, extension of these original observations to clinical contexts have proceeded in parallel. There is a growing body of data supporting the occurrence of preconditioning in humans under a variety of spontaneous3 4 and investigational circumstances.5 6 7 8 9 10 In the latter instance, however, surrogate markers of myocardial "protection" during PTCA, eg, ST-segment shift and clinical pain response, have been used as end points. The clinical relevance of these observations remains unclear.
Creatine kinase (CK) elevations after percutaneous coronary interventions have been reported.11 There is a growing awareness that elevation of this marker enzyme after coronary intervention has important prognostic significance11 12 and may be predictive of future events.12 13 14 The present study design tests the hypothesis that in a population of patients with unstable ischemic syndromes, PTCA performed in accordance with a standardized method of eliciting preconditioning would result in less CK elevation than would procedures performed without such an approach.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The study population consisted of 150 patients undergoing percutaneous coronary revascularization of a native coronary artery for a variety of unstable ischemic syndromes. Patients were randomly assigned (computer-generated code) to receive a previously validated sequence of balloon inflations that would elicit preconditioning (PC) or to an unrestricted approach to PTCA (UC). In all other respects, the remainder of the procedure was conducted at the discretion of the operator with respect to subsequent devices, use of adjunctive antithrombotic agents, and type of contrast media. All patients had determinations of creatine kinase (CK) blood levels at 8 and 12 hours after the procedure. In patients with elevated levels of either CK (normal range, 55 to 170 U/L in men, 30 to 135 U/L in women) or CK-MB (normal range, 0% to 3%) at 12 hours, repeat determinations at 24 hours were made.
The standardized protocol for inducing preconditioning during PTCA has been described5 and subsequently validated in additional populations.15 16 The protocol consists of a 90-second period of balloon occlusion of the target artery followed by a 5-minute period of reperfusion with the balloon withdrawn proximal to the lesion. A second 90-second period of balloon occlusion at the same inflation pressure is then performed. The ST segment response during these 2 periods of balloon occlusion is assessed from either the surface ECG or the intracoronary guidewire. An unrestricted approach to PTCA was defined as a single period of balloon occlusion for >1 minute (n=65) or multiple inflations of <60 seconds each without an intervening period of reperfusion (n=15).
Data Analysis
Summary data are represented as mean±SD for
continuous variables and percentages for dichotomous variables.
CK data were categorized as 1X<CK<2X, 2X<CK<5X, and CK>5X,
where X is the upper limit of normal. Between-group comparisons were
made with unpaired t tests or contingency tables.
Multivariable logistic regression was performed to assess the
independent contribution of clinical and procedural variables to
the end point of any CK elevation. A value of P<0.05 was
considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There were no significant differences (Table 1
) in demographic, clinical, or
angiographic features between patients in the preconditioning group
(PC) and those in the usual-care (UC) group. Moreover, there were no
differences between groups in the use of adjunctive IIb/IIIa
platelet antagonists during the procedure (PC, 9%; UC,
11%; P=NS), use of ionic (I) versus nonionic (NI) contrast
media (PC I/NI, 73%; UC I/NI, 70%; P=NS), or specific
device used.
|
The overall clinical success rate (residual stenosis <50% and
the absence of death, in-laboratory myocardial infarction, or emergent
bypass surgery) for the entire population was 94%. Therefore, by
definition, there was a 6% major adverse event rate, which was equally
distributed between groups (Table 2).
There were too few individual major adverse events to allow for
meaningful statistical analysis. Other periprocedural
(in-laboratory and within 24 hours of the procedure) adverse events are
recorded in Table 3. Again, there
were too few events in each group to allow for meaningful
comparison.
|
|
The overall rate of any CK elevation after percutaneous
revascularization procedures in this population was
16% (25 of 150 patients), and the rate of any CK-MB elevation was
22%. All subsequent analyses, however, will be restricted to
the patients with elevated total CK. The distribution of CK elevations
is shown in Figure 1. Notably, only 3 of
the 25 patients with an elevated CK had a >5-fold increase. As
expected, there was a significant relationship between CK elevation and
all adverse events (P=0.0001) as well as major in-laboratory
adverse events (P=0.04).
|
There was a significant difference in the rate of any CK elevation
between the PC and UC groups (Figure 2).
CK elevations were detected in 7.1% of the PC patients and in 25% of
the UC patients. This difference was highly significant
(P<0.005). The individual event rates within each group are
shown in Table 4. For any level of CK
elevation, the number of patients in the control group always exceeded
the number of patients undergoing PC. Because of the limited size of
the individual groups, meaningful statistical analysis is
precluded.
|
|
The strength of the relationship between preconditioning and CK release is expressed in the univariate odds ratio of 0.23 (95% CI, 0.06 to 0.69; P=0.0034). This relationship is preserved after adjustment for potential confounders. Multivariable analysis of preprocedural and intraprocedural variables revealed only the PC group (odds ratio, 0.25; 95% CI, 0.04 to 0.70) and all adverse events (odds ratio, 1.6; 95% CI, 1.05 to 5.4) as significant predictors of any CK elevation.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this randomized, prospectively designed study, the use of a protocol designed to elicit preconditioning during PTCA resulted in clinically relevant cardioprotection. Specifically, the likelihood of postprocedure CK release was reduced by 77% in patients undergoing a standardized preconditioning protocol in comparison with patients not receiving this protocol. These findings are particularly relevant given that the study population consisted entirely of patients with unstable ischemic syndromes, who are at a high risk of ischemic complications.
A considerable literature on ischemic preconditioning consists of characterization of the phenomenon, generalizability across species, mechanisms and potential metabolic pathways, modes of induction, and applicability to humans.2 17 With respect to the latter, there is ongoing controversy with respect to the phenomenon itself18 and its clinical relevance.19 Controversy surrounding the mechanism of cardioprotection conferred by sequential periods of brief ischemia separated by a period of reperfusion has engendered considerable discussion. A role for collateral blood flow enhancement during PTCA-mediated preconditioning has been adduced,9 18 although the majority of published studies support a collateral independent mechanism.1 5 7 20 21 22 23 Indirect evidence of the clinical relevance of PC exists in studies performed during PTCA in which ECG and metabolic markers of myocardial ischemia were diminished with preconditioning.5 15 Estimates of infarct size and clinical outcome in retrospective analyses of thrombolytic trials were improved in the setting of antecedent angina.3 4 More direct evidence exists in studies performed during open-heart surgery, in which markers of lessened ischemia and membrane integrity were observed in hearts subjected to a preconditioning stimulus.24 25 However, clinical outcomes were not reported.
Percutaneous revascularization procedures have been associated with markers of myocardial necrosis,11 particularly in high-risk settings. Notably, even in the absence of major intraprocedural or periprocedural adverse events, there appears to be a relationship between detectability of these markers and intermediate and long-term clinical outcome. Although the strength of this relationship is somewhat controversial,26 the significance of these observations is of great interest.14 27 Clearly, pharmacological28 29 or procedural strategies designed to minimize these perturbations may translate into improved clinical outcomes during percutaneous revascularization. In the present study, a simple, previously validated protocol designed to elicit the preconditioning response resulted in a lower frequency of CK release in a population at significant risk of CK release. Whether such a beneficial effect on CK release translates into improved long-term clinical outcome is as yet unanswered. It is of interest that preconditioning was not associated with fewer (major or minor) periprocedural adverse events (P=0.1), although the event rates were low in both groups. It is also important to note that of the 70 patients in the PC arm, 65 manifested either lessened pain and/or ST-segment shift during sequential balloon occlusion. Analysis confined to these patients yields conclusions identical to those reported above.
The mechanism whereby preconditioning exerts a beneficial effect on
procedure-related CK elevation cannot be answered by this type of
study. The results reported here, however, are entirely
consistent with the form of myocardial protection associated
with experimental and clinically observed preconditioning. The time
course for the induction of ischemic preconditioning observed
during PTCA has been well characterized. It has been noted that a
minimum of 60 to 90 seconds of initial balloon occlusion is necessary
to demonstrate lessened ischemia during subsequent
occlusion.5 9 18 Furthermore, the necessity for a
sufficient intervening period of reperfusion is
critical.30 The distribution of initial balloon occlusion
times in the UC group is shown in Figure 3. The mean occlusion time was 3.3±1.2
minutes in the group overall and 3.6±0.8 minutes in the 65 patients
with an occlusion >1 minute. Thus, the UC group sustained a period of
total occlusion time comparable to that in the PC group. The fact that
CK elevation was more frequent in the UC group than the PC group, given
the similarity in overall total ischemic duration, provides
additional support for the induction of preconditioning with sequential
90-second occlusions.
|
It is important to point out that previous studies have reported CK elevation in the absence of clinically evident periprocedural adverse events.12 Thus, it would appear that the adverse prognosis associated with CK release during coronary intervention may be independent of procedural mishaps. In the present study, there was a relationship between CK elevation and adverse events, although no relationship exists between preconditioning and adverse events. Although the failure to detect a relationship between preconditioning and adverse events may be the result of the small number of events, the acute (beneficial) effects of preconditioning on CK elevation may be the result of a true effect on adverse periprocedural events and/or a more fundamental cardioprotective effect.
This study was conducted in a population of patients with unstable ischemic syndromes. Such patients are known to be at high risk of ischemic complications during percutaneous intervention. No patient had elevated CK levels at baseline. The frequency of overall (any) CK elevation is within the range of previous reports,11 although the frequency of substantial elevations (>5 times normal) was surprisingly low. This may reflect the underrepresentation of various atherectomy modalities,30 the exclusion of saphenous vein graft interventions31 from the study, differences in patient population, or differences in procedural conduct. The protocol used for the induction of preconditioning, however, precludes the initial use of atherectomy devices. In addition, the use of intracoronary stents to minimize ischemic sequelae in high-risk situations also may contribute to a lower than expected adverse event rate. However, the frequencies of clinical, demographic, and anatomic correlates of procedural complications, including CK release,11 32 were equally distributed between the groups. Both univariate and multivariable analysis confirmed the potent influence of preconditioning on CK release and lend further support to the clinical relevance of preconditioning.
In summary, a standardized protocol of inducing preconditioning during PTCA resulted in a significant reduction in the rate of CK elevation in a high-risk population. Given the increasing evidence for such elevations as markers of altered medium- and long-term prognosis, the ability to favorably alter the rate of enzyme release provides important support for the clinical relevance of preconditioning. Studies designed to examine differences in clinical outcomes during long-term follow-up are in order.
|
Acknowledgments |
|---|
The author wishes to thank Cheré Raith and Susan Jaeger for their expert secretarial assistance and Dana Beach, RN, for her untiring efforts in obtaining the CK data.
Received October 20, 1998; revision received January 22, 1999; accepted January 29, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;75:1124–1136.
2. Jennings RB. Overview of preconditioning against lethal cell injury. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: Bios Scientific Publisher; 1996.
3.
Kloner RA, Shook T, Przyklenk K, David VG, Junio L,
Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, McCabe C,
Braunwald E, for the TIMI Investigators. Previous angina alters
in-hospital outcome in TIMI 4: a clinical correlate to preconditioning?
Circulation. 1995;91:37–47.
4. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Ruscateli F. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation. 1995;21:291–297.
5.
Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW,
Herrman HC, Laskey WK. Adaptation to ischemia during
percutaneous transluminal coronary angioplasty:
clinical, hemodynamic, and metabolic
features. Circulation. 1990;82:2044–2051.
6.
Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R.
Preconditioning of human myocardium with adenosine
during coronary angioplasty. Circulation. 1997;95:2500–2507.
7. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Polisca P, Chiarello L, Gioffre PA. Effects of A1 adenosine receptor blockade by bamiphylline on ischemic preconditioning during coronary angioplasty. Eur Heart J. 1966;17:846–853.
8. Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck JP. Aminophylline inhibits adaptation to ischemia during angioplasty: role of adenosine in ischaemic preconditioning: Eur Heart J. 1996, 17: 539–544.
9. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578–586.[Abstract]
10. Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol. 1996;28:1119–1126.[Abstract]
11.
Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ,
Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ,
Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman
RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after
revascularization procedures. J Am Coll
Cardiol. 1998;31:241–251.
12.
Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis
SG. Significance of mild transient release of creatine-kinase MB
fraction after percutaneous coronary
interventions. Circulation. 1996;94:1528–1536.
13.
Kong TQJ, Davidson CJ, Meyers SN, Tauke JT, Parker MA,
Bonow RO, Prognostic implication of creatine kinase elevation following
elective coronary artery interventions. JAMA. 1997;277:461–466.
14.
Ohman EM, Tardiff BE. Periprocedural cardiac marker
elevation after percutaneous coronary artery
revascularization: importance and implications.
JAMA. 1997;277:495–497.
15. Vaitkus PT, Miller JM, Buxton AE, Josephson ME, Laskey WK. Ischemia-induced changes in human endocardial electrograms during percutaneous transluminal coronary angioplasty. Am Heart J. 1994;127:1481–1490.[Medline] [Order article via Infotrieve]
16. Lim R, Laskey WK. Ischemic preconditioning in unstable coronary syndromes: evidence for time dependence. J Am Coll Cardiol. 1997;30:1461–1465.[Abstract]
17.
Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E.
Medical and cellular implications of stunning, hibernation and
preconditioning: an NHLBI workshop. Circulation. 1998;97:1848–1867.
18. Dupouy P, Geschwind H, Pelle G, Aptear E, Hittinger L, Ghalid AE, Dubois-Rande JH. Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans. J Am Coll Cardiol. 1996;27:1374–1380.[Abstract]
19. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol. 1994;24:1133–1142.[Abstract]
20. Sakata Y, Kodama K, Kitakaze M, Masuyuma T, Hirayama A, Lim Y-J, Ishikura F, Sakai A, Adachi T, Hori M. Different mechanisms of ischemic adaptation to repeated coronary occlusion in patients with and without recruitable collateral circulation. J Am Coll Cardiol. 1997;30:1679–1686.[Abstract]
21.
Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson
DH, Downey JM. Protection against infarction afforded by
preconditioning is mediated by the adenosine receptors in
rabbit heart. Circulation. 1991;84:350–356.
22. Leesar MA, Stoddard M, Ahmed M, Broadbeat MM, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation. 1997;95:2100–2107.
23.
Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS,
Depaulis R, Chiarello L, Gioffre PA. Phentolamine prevents
adaptation to ischemia during coronary angioplasty:
role of 
-adrenergic receptors in ischemic
preconditioning. Circulation. 1997;96:2171–2177.
24. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276–277.[Medline] [Order article via Infotrieve]
25.
Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper
J, Yellon DM. Ischemic preconditioning reduces troponin T
release in patients undergoing coronary artery bypass surgery.
Heart. 1997;77:314–318.
26. Lim R, Zawacki K, Laskey WK. Creatine kinase release after catheter-based coronary intervention. Cathet Cardiovasc Diagn. 1977;41:117–119.
27.
Abdelmeguid AE, Topol EJ. The myth of the myocardial
"infarctlet" during percutaneous coronary
revascularization procedures.
Circulation. 1996;94:3369–3375.
28.
The EPIC Investigators. Use of a monoclonal antibody
directed against the platelet glycoprotein IIb/IIIa
receptor in high risk coronary angioplasty. N Engl
J Med. 1994;330:956–961.
29.
Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG,
Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
Long term protection from myocardial ischemic events in a
randomized trial of brief integrin B3 blockade with
percutaneous coronary intervention.
JAMA. 1997;278:479–484.
30. Tanaka T, Oka Y, Tawara I, Sada T, Kiru Y. Effect of time interval between two balloon inflations in ischemic preconditioning during coronary angioplasty. Cathet Cardiovasc Diagn. 1997;42:263–267.[Medline] [Order article via Infotrieve]
31. Redwood SR, Popma JJ, Kent KM. Predictors of late mortality following ablative new-device angioplasty in native coronary arteries. J Am Coll Cardiol. 1996;27(suppl A):167A–168A. Abstract.
32. Liu MW, Douglas JS Jr, Lembo NJ, King SB III. Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. Am J Cardiol. 1993;72:514–517.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  E K Iliodromitis, S Kyrzopoulos, I A Paraskevaidis, K G Kolocassides, S Adamopoulos, G Karavolias, and D T Kremastinos Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart, December 1, 2006; 92(12): 1821 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kloner and S. H. Rezkalla Preconditioning, postconditioning and their application to clinical cardiology Cardiovasc Res, May 1, 2006; 70(2): 297 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Penna, G. Alloatti, S. Cappello, D. Gattullo, G. Berta, B. Mognetti, G. Losano, and P. Pagliaro Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2512 - H2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Barthel, D. Ebel, J. Mullenheim, D. Obal, B. Preckel, and W. Schlack Effect of lidocaine on ischaemic preconditioning in isolated rat heart Br. J. Anaesth., November 1, 2004; 93(5): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Crisafulli, F. Melis, F. Tocco, U. M. Santoboni, C. Lai, G. Angioy, L. Lorrai, G. Pittau, A. Concu, and P. Pagliaro Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H235 - H242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Nallamothu and E. R. Bates Periprocedural myocardial infarction and mortality: Causality versus association J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1412 - 1414. [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Laskey and D. Beach Frequency and clinical significance of ischemic preconditioning during percutaneous coronary intervention J. Am. Coll. Cardiol., September 17, 2003; 42(6): 998 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Bovill Anesthesia for Patients with Impaired Ventricular Function Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 49 - 54. [PDF]
|
|
|
|
 |
|
 R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text]
|
|
|
|
|
|
R. A Kloner, M. T Speakman, and K. Przyklenk Ischemic preconditioning: a plea for rationally targeted clinical trials Cardiovasc Res, August 15, 2002; 55(3): 526 - 533. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iwado, K. Mizushige, K. Manabe, Y. Wada, I. Kondo, K. Ohmori, and M. Kohno Suppression of Fatty Acid Metabolism After Exercise Stress in Patients with No Electrocardiographic ST Segment Shift During Balloon Angioplasty Angiology, December 1, 2001; 52(12): 841 - 849. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Costa, R. G. Carere, S. V. Lichtenstein, D. P. Foley, V. de Valk, W. Lindenboom, P. C.H. Roose, T. R. van Geldorp, C. Macaya, J. L. Castanon, et al. Incidence, Predictors, and Significance of Abnormal Cardiac Enzyme Rise in Patients Treated With Bypass Surgery in the Arterial Revascularization Therapies Study (ARTS) Circulation, November 27, 2001; 104(22): 2689 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Heusch Nitroglycerin and Delayed Preconditioning in Humans : Yet Another New Mechanism for an Old Drug? Circulation, June 19, 2001; 103(24): 2876 - 2878. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||